Due to the functions of the 4 m6A-related gene signature described above, we assessed the drug resistance of these 4 hub genes in CARE dataset, and ultimately found that the CARE scores of CBLL1 were higher than 0 in CCLE, CGP and CTRP, which indicated that CBLL1 may be a potential prognostic target for reversing tumor progression in LC. The gene discussed is CBLL1; the disease is laryngotracheoesophageal cleft.